keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibits αvβ6 and αvβ1-induced activation of TGF-β, and can be used for the study of idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 125.00 | |
5 mg | In stock | $ 457.00 | |
10 mg | In stock | $ 789.00 | |
25 mg | In stock | $ 1,370.00 | |
50 mg | In stock | $ 2,324.00 | |
100 mg | In stock | $ 3,818.00 |
Description | Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibits αvβ6 and αvβ1-induced activation of TGF-β, and can be used for the study of idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP). |
Targets&IC50 | αvβ1:3.4 nM (Kd), αvβ6:5.7 nM (Kd) |
In vitro | Bexotegrast (PLN-74809; 1.82 µM; incubation for 7 days) can dose-dependently inhibit lung collagen deposition and phosphorylation of Smad3[2]. |
In vivo | Bexotegrast(PLN-74809;100–500 mg/kg), administered orally to mice 7 to 21 days after bleomycin-induced lung injury, dose-dependently reduces interstitial fibrotic collagen deposition caused by bleomycin and blocks Smad3 phosphorylation [2]. |
Synonyms | PLN-74809 |
Molecular Weight | 492.61 |
Formula | C27H36N6O3 |
CAS No. | 2376257-44-0 |
keep away from direct sunlight,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (202.83 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bexotegrast 2376257-44-0 Cytoskeletal Signaling Integrin PLN-74809 inhibitor inhibit